CRYOPORT, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
CRYOPORT, INC. (CYRX) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $560.52 million as of 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2023-05-04
- 2023-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $560.52M.
- 2022-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $555.84M.
- 2022-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $555.72M.
- 2022-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $568.42M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2023-03-31 | $560.52M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $555.84M 10-Q · filed 2023-05-04 | |
| 2022-09-30 | $555.72M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $568.42M 10-Q · filed 2022-11-04 | |
| 2022-03-31 | $609.43M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $641.83M 10-Q · filed 2023-05-04 | |
| 2021-09-30 | $647.23M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $648.03M 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $647.27M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $382.70M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $120.04M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $126.66M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $127.30M 10-Q · filed 2021-08-06 | $127.31M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $126.28M 10-K · filed 2023-02-28 | |
| 2018-12-31 | $38.55M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |